Physician profile
Omar Eton
NPI 1275736050
$31,443.58
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,197 · 2021: $1,001 · 2022: $217 · 2023: $12K · 2024: $52.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,405 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,270 · Food and Beverage: $516 · Travel and Lodging: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,405.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,270.00 |
| Food and Beverage | $515.88 |
| Travel and Lodging | $452.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24,337.70 | 2019-2024 | Keytruda |
| Foundation Medicine, INC. | $5,196.73 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,230.74 | 2019-2023 | |
| Eisai INC. | $312.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $205.96 | 2019 | |
| Rigel Pharmaceuticals, INC. | $122.06 | 2021 | |
| Janssen Biotech, INC. | $24.72 | 2024 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $13.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Eton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.